About Us

About Us

Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Our programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems.

Bremelanotide for the treatment of female sexual dysfunction is our lead product in development, and is currently in pivotal Phase 3 clinical trials. We also have development programs or drug candidates for heart failure, pulmonary diseases, obesity, inflammatory and dermatologic diseases and erectile dysfunction.